These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34350562)

  • 21. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-Nguanmoo P; Theamboonlers A; Poovorawan Y
    Hepatol Res; 2010 Apr; 40(4):269-77. PubMed ID: 20070399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.
    Tatsukawa Y; Tsuge M; Kawakami Y; Hiyama Y; Murakami E; Kurihara M; Nomura M; Tsushima K; Uchida T; Nakahara T; Miki D; Kawaoka T; Abe-Chayama H; Imamura M; Aikata H; Ochi H; Hayes CN; Kawakami H; Chayama K
    Antivir Ther; 2018; 23(8):639-646. PubMed ID: 29856363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
    Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
    Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
    Al Ashgar H; Peedikayil MC; Al Quaiz M; Al Sohaibani F; Al Fadda A; Khan MQ; Thoralsson E; Al Thawadi S; Al Jedai A; Al Kahtani K
    Saudi J Gastroenterol; 2017; 23(3):190-198. PubMed ID: 28611343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
    Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
    [No Abstract]   [Full Text] [Related]  

  • 27. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
    Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Wu SL; Chang M; Liu RY; Hu LP; Li ZZ; Hua WH; Song SJ; Xie Y
    Chin Med J (Engl); 2017 Mar; 130(5):559-565. PubMed ID: 28229987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pegylated interferon-α2b add-on therapy on renal function in chronic hepatitis B patients: A real-world experience.
    Peng MJ; Guo XQ; Zhang WL; Chen J; Kang W; Yang XF; Guo Y; Zhang Y
    Front Microbiol; 2022; 13():980250. PubMed ID: 36329842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B.
    Zheng C; Yan H; Zeng J; Cai S; Wu X
    Infect Drug Resist; 2019; 12():845-854. PubMed ID: 31114265
    [No Abstract]   [Full Text] [Related]  

  • 32. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
    Zhu SS; Dong Y; Zhang HF; Wang LM; Xu ZQ; Zhang M; Gan Y; Chen DW; Wang FC; Yan JG; Zhao P
    Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):604-609. PubMed ID: 31594077
    [No Abstract]   [Full Text] [Related]  

  • 34. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients.
    Broquetas T; Garcia-Retortillo M; Micó M; Canillas L; Puigvehí M; Cañete N; Coll S; Viu A; Hernandez JJ; Bessa X; Carrión JA
    World J Hepatol; 2020 Nov; 12(11):1076-1088. PubMed ID: 33312431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study.
    Lee JH; Lee YB; Cho EJ; Yu SJ; Yoon JH; Kim YJ
    Clin Infect Dis; 2021 Nov; 73(9):e3308-e3316. PubMed ID: 32556157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
    Yu SL; Guo CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy.
    Cao Z; Meng S; Zheng Y; Wang J; Wang R; Chen X
    Innate Immun; 2020 Oct; 26(7):601-608. PubMed ID: 32772775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a.
    Chen X; Mao Q; Xie Y; Dou X; Xie Q; Sheng J; Gao Z; Zhou X; Liu Y; Zheng H; Zhang S; Li S; Zhu F; Xu Y; Zhang M; Hu Y; Chen X; Huang Y; Ren H; Jia J
    J Clin Transl Hepatol; 2019 Sep; 7(3):249-257. PubMed ID: 31608217
    [No Abstract]   [Full Text] [Related]  

  • 40. Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up.
    Brouwer WP; Chan HL; Brunetto MR; Martinot-Peignoux M; Arends P; Cornberg M; Cherubini B; Thompson AJ; Liaw YF; Marcellin P; Janssen HL; Hansen BE;
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1481-1489.e5. PubMed ID: 26872398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.